EURORDIS

EURORDIS
source
Name	EURORDIS
Type	Non-profit patient-driven alliance
Founded	1997
Headquarters	Paris, France
Area served	Europe
Focus	Rare diseases, patient advocacy, research

EURORDIS EURORDIS is a European non-profit alliance representing patient organizations for rare diseases. It connects networks across countries, influencing public policy, research, and care by mobilizing stakeholders in the European Union, Council of Europe, World Health Organization, and other international forums. The organization works with patient groups, academic consortia, pharmaceutical companies, regulatory agencies, and health technology assessment bodies to accelerate research, improve diagnosis, and promote access to therapies.

History

Established in 1997 in Paris, the organization emerged amid increasing cross-border collaboration following the Maastricht Treaty and enlargement of the European Union. Early activities intersected with initiatives from the European Commission, the Council of Europe, and patient movements inspired by groups such as EURORDIS Rare Disease Europe contemporaries including National Organization for Rare Disorders and networks like Orphanet. Engagements with regulatory milestones such as the Orphan Drug Regulation (EC) No 141/2000 and interactions with the European Medicines Agency shaped its agenda. Over subsequent decades the alliance partnered with research projects funded under successive Framework Programmes for Research and Technological Development and Horizon 2020, while dialogues with institutions including the World Health Organization and United Nations elevated rare disease agendas globally.

Mission and Objectives

The alliance aims to improve the lives of people affected by rare diseases by advancing diagnosis, care, treatment, and social inclusion. Core objectives align with policy instruments and stakeholders such as the European Commission, European Parliament, Committee of the Regions, and national health authorities. It promotes patient-centric approaches compatible with standards from bodies like the European Reference Networks and collaborates on clinical trial frameworks regulated by the European Medicines Agency and national competent authorities. Advocacy priorities mirror international efforts from organizations such as Rare Diseases International and align with research consortia like International Rare Diseases Research Consortium.

Governance and Structure

Governance combines a volunteer Board and an executive Secretariat based in Paris, interacting with advisory fora that include representatives from member organizations, professional societies, and research centers such as Institut Pasteur and university hospitals across France, Germany, United Kingdom, Italy, and other Member States. Decision-making takes place through statutory instruments, annual General Assemblies, and steering committees similar to governance models used by entities like Médecins Sans Frontières and European Patients' Forum. Strategic partnerships involve legal frameworks comparable to those employed by international non-governmental organizations working with institutions like the Council of the European Union and Organisation for Economic Co-operation and Development.

Activities and Programs

Programs include patient registries, research projects, training for patient advocates, and awareness campaigns that collaborate with academic partners such as Karolinska Institute, University College London, Charité – Universitätsmedizin Berlin, and networks like Orphanet and European Reference Networks (ERNs). The alliance organizes conferences and symposia similar in scope to events by World Health Organization and European Congress of Rare Diseases participants, and supports data initiatives interoperable with standards promoted by European Bioinformatics Institute and the Global Alliance for Genomics and Health. It also facilitates patient involvement in clinical trial design alongside sponsors from the pharmaceutical sector such as Novartis, Pfizer, Roche, and biotech firms active in orphan drug development.

Advocacy and Policy Influence

The alliance engages in policy advocacy with legislative bodies including the European Parliament and executive institutions like the European Commission, contributing to consultations on regulation, reimbursement, and health technology assessment with agencies such as the European Medicines Agency and national HTA bodies. It lobbies for rare disease plans referencing national examples from France, Spain, Sweden, and Belgium, and coordinates campaigns that intersect with civil society actors including European Disability Forum and patient coalitions such as National Organization for Rare Disorders and Rare Diseases International. The alliance participates in stakeholder dialogues alongside industry associations like European Federation of Pharmaceutical Industries and Associations and academic consortia funded by Horizon Europe.

Partnerships and Funding

Funding and partnerships combine public grants, philanthropic support, membership fees, and project-based contracts. Donors and partners include European institutional programs such as Horizon 2020, foundations like the Wellcome Trust and Bill & Melinda Gates Foundation (when relevant to collaborative projects), national research agencies, and corporate partnerships with biopharmaceutical firms including Sanofi, AstraZeneca, and specialized orphan drug companies. Collaborations extend to research infrastructures such as European Bioinformatics Institute, patient networks like Genetic Alliance, and health services providers across Member States. Financial oversight follows nonprofit best practices used by international NGOs and aligns reporting with standards expected by multilateral funders such as the World Bank and Council of Europe oversight mechanisms.

Category:Patient organizations Category:Non-governmental organizations based in France